Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma

Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer

NCT01501630 ·Status: COMPLETED

FDG PET/CT in Breast Cancer Bone Mets

NCT01996046 ·Status: ACTIVE_NOT_RECRUITING

Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort

NCT02356497 ·Status: RECRUITING

Evaluation of the Metastasis and Recurrence of Prostate Cancer

NCT03507595 ·Status: UNKNOWN

Assessment of the Accuracy of PET/MR in Detection and Monitoring Response of Bone Metastases

NCT04159376 ·Status: UNKNOWN ·Phase: NA

Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy

NCT04942275 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma

NCT02876991 ·Status: UNKNOWN ·Phase: NA

Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life

NCT02839291 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

NCT00392938 ·Status: COMPLETED

Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium

NCT03105869 ·Status: COMPLETED ·Phase: NA

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

NCT04272658 ·Status: RECRUITING

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

NCT00956163 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions

NCT05934994 ·Status: RECRUITING ·Phase: NA

Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS)

NCT02876731 ·Status: COMPLETED ·Phase: NA

Prognostic PET/CT Model in Non Small Cell Lung Cancer

NCT03199599 ·Status: COMPLETED

Management of Bone Metastases

NCT06713941 ·Status: ACTIVE_NOT_RECRUITING

MRI Perfusion on T1 and T2 Brain Lesion(s)

NCT02250755 ·Status: COMPLETED ·Phase: NA

Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

NCT02376127 ·Status: COMPLETED

Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin

NCT05977803 ·Status: RECRUITING ·Phase: NA

Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis

NCT05762172 ·Status: COMPLETED ·Phase: NA

Role of SPECT/CT of Bone Scan in Charactarization of Bone Lesions

NCT07248033 ·Status: NOT_YET_RECRUITING

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

NCT00936975 ·Status: COMPLETED ·Phase: PHASE2

18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.

NCT01927939 ·Status: UNKNOWN

Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES

NCT03873428 ·Status: RECRUITING ·Phase: NA

The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

NCT03619044 ·Status: TERMINATED ·Phase: NA